FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Hair Loss

Minoxidil Topical Solution 2% for Women (by Alpharma), Approved April 1997
Generic equivalent of Rogaine

Head and Neck Cancer

Keytruda (pembrolizumab) (by Merck), Approved August 2016
For the treatment of head and neck squamous cell cancer

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved November 2016
For the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck

Head Lice

Sklice (ivermectin) lotion (by Sanofi Pasteur), Approved February 2012
For the treatment of head lice

Heart Attack (Myocardial Infarction)

Kengreal (cangrelor) (by The Medicines Company), Approved June 2015
For reducing periprocedural thrombotic events

Retavase (reteplase) (by Boehringer Mannheim Corporation), Approved November 1996
Treatment for patients suffering from heart attack

Heart Disease

Pravachol (pravastatin sodium) (by Bristol-Myers Squibb), Approved April 1996
Treatment for heart disease

Heart Failure

BiDil (isosorbide dinitrate/hydralazine hydrochloride) (by NitroMed), Approved June, 2005
For the treatment of heart failure in black patients

Corlanor (ivabradine) (by Amgen), Approved April 2015
For the treatment of chronic heart failure

Entresto (sacubitril and valsartan) (by Novartis), Approved July 2015
For the treatment of chronic heart failure

Prinivil or Zestril (Lisinopril) (by Merck, Zeneca), Approved November 24, 1995
Treatment for hypertension, heart failure, and acute myocardial infarction

Toprol-XL (metoprolol succinate) (by AstraZeneca), Approved January 1995
For the treatment of hypertension, angina pectoris and heart failure

Heart Transplantation

CellCept (by Roche), Approved February 1998
Treatment for the prevention of organ rejection inpatients undergoing heart transplants

Heartburn

Axid AR (nizatidine (by Whitehall-Robins Healthcare), Approved May 1996
Over-the-counter anti-ulcer treatment

Cimetidine Hydrochloride Oral Solution (by Pharmaceutical Formulations), Approved June 1998
Generic equivalent of Tagamet HB 200

Cimetidine Hydrochloride Oral Solution (by Hi-Tech Pharmacal), Approved October 1997
Generic equivalent of Tagamet Oral Solution, 300 mg/5 ml

Pepcid Complete (by Merck), Approved October 2000
For use in the relief of heartburn associated with acid indigestion and sour stomach

PREVACID(R) (lansopraxole) (by TAP Pharmaceuticals), Approved April 1998
Treatment of heartburn associated with GERD

Prilosec (omeprazole) (by Astra Merck), Approved January 1998
Treatment for heartburn

Ranitidine Capsules (by Geneva Pharmaceuticals), Approved October 1997
Generic equivalent of Zantac GELdose

Zantac 75 Efferdose (by GlaxoSmithKline), Approved March 1998
Treatment for heartburn

Hematological Disorders

Soliris (eculizumab) (by Alexion), Approved March 2007
For the treatment of paroxysmal nocturnal hemoglobinuria

Soliris (eculizumab) (by Alexion), Approved September 2011
For the treatment of atypical hemolytic uremic syndrome

Veltassa (patiromer) (by Relypsa), Approved October 2015
For the treatment of hyperkalemia

Hemodialysis

Parsabiv (etelcalcetide) (by Amgen), Approved February 2017
For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis

Hemophilia

Afstyla (Antihemophilic Factor (Recombinant), Single Chain) (by CSL Behring), Approved May 2016
For the treatment of hemophillia A

AlphaNine SD Coagulation Factor IX (Human) (by Alpha Therapeutic Corporation), Approved July 1996
Treatment for the prevention and control of bleeding in subjects with hemophilia

Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] (by Biogen Idec), Approved March 2014
For the treatment of hemophilia B

BeneFIX (coagulation Factor IX (recombinant)) (by Genetics Institute), Approved February 1997
Treatment for hemophilia B

Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] (by Biogen IDEC.), Approved June 2014
For the treatment of hemophillia A

Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) (by CSL Behring), Approved March 2016
For the treatment of hemophilia B

Kogenate FS (Antihemophilic Factor Recombinant) (by Bayer), Approved June 2000
For the treatment of hemophilia A

Kovaltry [Antihemophilic Factor (Recombinant)] (by Bayer ), Approved March 2016
For the treatment of hemophillia A

Nuwiq (recombinant Factor VIII) (by Octapharma), Approved September 2015
For the prophylaxis and treatment of hemophilia A

Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] (by Baxter), Approved October 2014
For the treatment of acquired hemophilia A

Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) (by Novo Nordisk), Approved June 2017
For the treatment of hemophilia B

Rixubis (Coagulation Factor IX (Recombinant)] (by Baxter International), Approved June 2013
For the routine prophylaxis and control of hemophilia B

Hemorrhage

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Natazia (estradiol valerate and estradiol valerate/dienogest) (by Bayer), Approved March 2012
For the treatment of heavy menstrual bleeding

Praxbind (idarucizumab) (by Boehringer Ingelheim), Approved October 2015
For the reversal of the anticoagulant effects of dabigatran

Tretten (Coagulation Factor XIII A-Subunit [Recombinant]) (by Novo Nordisk), Approved December of 2013
For the treatment of congenital factor XIII (FXIII) A-subunit deficiency

Hepatic Encephalopathy

Xifaxan (rifaximin) (by Salix Pharmaceuticals), Approved May 2004
For the treatment of Travelers' diarrhea caused by noninvasive strains of Escherichia coli

Hepatitis

Harvoni (ledipasvir and sofosbuvir) (by Gilead), Approved October 2014
For the treatment of hepatitis C

Havrix (by SmithKline Beecham), Approved March 1996
Treatment for hepatitis A

Olysio (simeprevir) (by Janssen Therapeutics), November of 2013
For the treatment of hepatitis C

Sovaldi (sofosbuvir) (by Gilead Sciences), December of 2013
For the treatment of hepatitis C

Twinrix (by GlaxoSmithKline), Approved May 2001
For the prevention of hepatitis A and B

Hepatitis B

Baraclude (entecavir) (by Bristol-Myers Squibb), Approved March, 2005
For the treatment of chronic hepatitis B infections with evidence of active viral replication

Hepsera (adefovir dipivoxil) (by Gilead), Approved September 2002
For the treatment of chronic hepatitis B in adults with evidence of active viral replication

Pediarix Vaccine (by GlaxoSmithKline), Approved December 2002
For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old.

Twinrix (by GlaxoSmithKline), Approved May 2001
For the prevention of hepatitis A and B

Tyzeka (telbivudine) (by Idenix Pharma), Approved October 2006
For the treatment of hepatitis B virus

Vemlidy (tenofovir alafenamide) (by Gilead Sciences), Approved November 2016
For the treatment of chronic hepatitis B

Viread (tenofovir disoproxil fumarate) (by Gilead), Approved August 2008
For the treatment of hepatitis B

Hepatitis C; Chronic

Daklinza (daclatasvir) (by Bristol-Myers Squibb), Approved July 2015
For the treatment of chronic HCV genotype 3

Epclusa (sofosbuvir and velpatasvir) (by Gilead Sciences), Approved June 2016
For the treatment of hepatitis C

Harvoni (ledipasvir and sofosbuvir) (by Gilead), Approved October 2014
For the treatment of hepatitis C

Incivek (telaprevir) (by Vertex Pharmaceuticals), Approved May 2011
For the treatment of genotype 1 chronic hepatitis C

INFERGEN (interferon alfacon-1) (by Amgen), Approved October 1997
Treatment for chronic hepatitis C virus

Intron A (interferon alfa-2b, recombinant) (by Schering-Plough), Approved March 1997
Treatment for hepatitis C

Mavyret (glecaprevir and pibrentasvir) (by AbbVie), Approved August 2017
For the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6

Olysio (simeprevir) (by Janssen Therapeutics), November of 2013
For the treatment of hepatitis C

Pegasys (peginterferon alfa-2a) (by Roche), Approved October 2002
For the treatment of chronic hepatitis C who have compensated liver disease

Peg-Intron (peginterferon alfa-2b) (by Schering-Plough), Approved January 2001
For the treatment of chronic hepatitis C

Rebetol (ribavirin) (by Schering-Plough), Approved July 2001
For the treatment of chronic hepatitis C

REBETRON (TM) Combination Therapy (by Schering-Plough), Approved June 1998
Treatment for Chronic Hepatitis C

Sovaldi (sofosbuvir) (by Gilead Sciences), December of 2013
For the treatment of hepatitis C

Technivie, (ombitasvir, paritaprevir and ritonavir) (by Abbvie), Approved July 2015
For the treatment of chronic HCV genotype 4

Victrelis (boceprevir) (by Merck), Approved May 2011
For the treatment of chronic hepatitis C genotype 1

Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) tablets (by Abbvie), Approved December 2014
For the treatment of genotype 1 chronic hepatitis C virus

Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) (by Gilead), Approved July 2017
For the treatment of hepatitis C

Zepatier (elbasvir and grazoprevir) (by Merck), Approved January 2016
For the treatment of chronic HCV genotypes 1 or 4

Hereditary Angioedema

Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) (by CSL Behring), Approved June 2017
For the routine prophylaxis to prevent Hereditary Angioedema attacks

Berinert (C1 Esterase Inhibitor (Human)) (by CSL Behring), Approved October 2009
For the treatment of abdominal or facial attacks of hereditary angioedema

Kalbitor (ecallantide) (by Dyax), Approved November 2009
For the treatment of hereditary angioedema

Ruconest (C1 esterase inhibitor [recombinant]) (by Pharming Group), Approved July 2014
For the treatment of hereditary angioedema

Herpes Simplex Infections

ABREVA (docosanol) (by AVANIR PHARMACEUTICALS), Approved July 2000
Cold sore/fever blister

Famvir (famciclovir) (by SmithKline Beecham), Approved September 17, 1997
Treatment for genital herpes

Valtrex (valacyclovir HCl) (by GlaxoSmithKline), Approved December 1995
Treatment for recurrent genital herpes

Viroptic (by King Pharmaceuticals), Approved February 1998
Treatment for inflammation of the cornea in children due to herpes simplex virus

Herpetic Neuralgia

Gralise (gabapentin) (by Abbott Laboratories), Approved February 2011
For the treatment of postherpetic neuralgia

High Blood Pressure (Hypertension - Pediatric)

Edarbi (azilsartan medoxomil) (by Takeda), Approved February 2011
For the treatment of hypertension

High Blood Pressure (Hypertension)

Amturnide (aliskiren + amlodipine + hydrochlorothiazide) (by Novartis), Approved December 2010
For the treatment of uncontrolled hypertension

Atacand (candesartan cilexetil) (by AstraZeneca), Approved September 2000
For the treatment of hypertension

Azor (amlodipine besylate; olmesartan medoxomil) (by Daiichi Sankyo), Approved September 2007
For the treatment of hypertension

Benicar (by Daiichi Sankyo), Approved April 2002
Oral tablet for the treatment of hypertension

Byvalson (nebivolol and valsartan) (by Allergan), Approved June 2016
For the treatment of hypertension

Caduet (amlodipine/atorvastatin) (by Pfizer), Approved January 2004
For the treatment of hypertension, chronic stable angina and vasospastic angina

Captopril and hydrochlorotiazide (by Mylan Laboratories), Approved May 1997
Treatment for hypertension

Cleviprex (clevidipine) (by The Medicines Company), Approved August 2008
For the treatment of hypertension when oral therapy is not feasible or not desirable

Corlopam (by Neurex), Approved September 1997
Treatment for severe high blood pressure

Diltiazem HCL, Extended-Release Capsules (by Biovail Laboratories), Approved January 2000
For the reduction of high blood pressure

Diovan (valsartan) (by Ciba Pharmaceuticals), Approved January 1997
Treatment for hypertension

Diovan (valsartan) (by Novartis), Approved January 1997 (capsules); July 2001 (tablets)
Oral capsules and tablets for the treatment of hypertension

Diovan HCT (valsartan) (by Novartis), Approved March 1998
Treatment for hypertension

DynaCirc CR (by Novartis), Approved February 1997
Treatment for hypertension

Edarbi (azilsartan medoxomil) (by Takeda), Approved February 2011
For the treatment of hypertension

Edarbyclor (azilsartan medoxomil and chlorthalidone) (by Takeda), Approved December of 2011
For the treatment of hypertension

Inspra (eplerenone tablets) (by Pharmacia & Upjohn), Approved September 2002
Oral tablets for the treatment of high blood pressure.

Lexxel (enalapril maleate-felodipine ER) (by Astra Merck), Approved January 1997
Treatment for hypertension

Mavik (trandolapril) (by Knoll Pharmaceutical), Approved May 1996
Treatment for hypertension

Micardis HCT (telmisartan and hydrochlorothiazide) (by Boehringer Ingelheim), Approved November 2000
For the treatment of hypertension

Microzide (hydrochlorothiazide) (by Watson Pharmaceuticals), Approved January 1997
Treatment for mild-to moderate hypertension

Pindolol (by Teva Pharmaceutical), Approved April 1997
Generic equivalent of Visken

Posicor (by Roche), Approved June 1997
Treatment for hypertension and chronic stable angina pectoris

Prestalia (perindopril arginine and amlodipine besylate) (by Symplmed Pharmaceuticals), Approved January 2015
For the treatment of hypertension

Prinivil or Zestril (Lisinopril) (by Merck, Zeneca), Approved November 24, 1995
Treatment for hypertension, heart failure, and acute myocardial infarction

Teczem (enalapril maleate/diltiazem malate) (by Hoechst Marion Roussel), Approved October 1996
Treatment for hypertension

Tekamlo (aliskiren + amlodipine) (by Novartis), Approved August 2010
For the treatment of hypertension

Tekturna (aliskiren) (by Novartis), Approved March 2007
For the treatment of hypertension

Teveten (eprosartan mesylate plus hydrochlorothiazide) (by Unimed Pharmaceuticals), Approved November 2001
Tablets for the treatment of hypertension

Teveten (eprosartan mesylate) (by SmithKline Beecham), Approved December 1997
Treatment for hypertension

Tiazac (diltiazem hydrochloride) (by Forest Laboratories), Approved February 1996
Treatment for hypertension

Toprol-XL (metoprolol succinate) (by AstraZeneca), Approved January 1995
For the treatment of hypertension, angina pectoris and heart failure

Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide) (by Daiichi Sankyo), Approved July 2010
For the treatment of hypertension

Verapamil (by IVAX), Approved December 1997
Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR

High Cholesterol (Hyperlipidemia)

Advicor (extended-release niacin/lovastatin) (by Kos Pharmaceuticals), Approved December 2001
For the treatment of cholesterol disorders

Juxtapid (lomitapide) (by Aegerion Pharmaceuticals), Approved December of 2012
For the treatment of homozygous familial hypercholesterolemia

Kynamro (mipomersen sodium) (by Genzyme), Approved January 2013
For the treatment of homozygous familial hypercholesterolemia

Lescol XL (fluvastatin sodium) tablet, extended release (by Novartis), Approved October 2000
For the use as an adjunct to diet to reduce elevated total cholesterol

Pravachol (pravastatin sodium) (by Bristol-Myers Squibb), Approved July 1996
Treatment for cholesterol-lowering

Repatha (evolocumab) (by Amgen), Approved August 2015
For the treatment of high cholesterol

Tricor (fenofibrate) (by Abbott Laboratories), Approved September 2001
For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia

Hip Replacement

Lovenox (enoxaparin sodium) Injection (by Rhone Poulenc Rorer), Approved February 1998
Treatment for prevention of blood clots following hip-replacement surgery

HIV

Aptivus (tipranavir) (by Boehringer Ingelheim), Approved June 2008
For the treatment of HIV

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) (by Gilead), Approved August of 2011
For the treatment of HIV-1 in treatment-naive adults

Confide (by Johnson & Johnson), Approved May 1996
HIV testing and counseling service

Descovy (emtricitabine and tenofovir alafenamide) (by Gilead), Approved April 2016
For the treatment of HIV-1 infection

Edurant (rilpivirine) (by Tibotec), Approved May 2011
For the treatment of HIV-1

Evotaz (atazanavir and cobicistat) (by Bristol-Myers Squibb), Approved January 2015
For the treatment of HIV-1 infection

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) (by Gilead Sciences), Approved November 2015
For the treatment of HIV-1 infection

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide) (by Gilead Sciences), Approved March 2016
For the treatment of HIV-1 as initial therapy

Prezcobix (darunavir and cobicistat) (by Janssen), Approved January 2015
For the treatment of HIV-1 infection

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) (by Gilead), Approved August 2012
For the treatment of HIV-1 infection

Tivicay (dolutegravir) (by ViiV HealthCare), Approved August 2013
For the treatment of HIV-1 in adults and children over 12 years of age

Triumeq (abacavir, dolutegravir, and lamivudine) (by ViiV HealthCare), Approved August 2014
For the treatment of HIV-1

Western blot confirmatory device (by Epitope), Approved in December 1995
Confirmatory test for HIV

Zerit (stavudine) (by Bristol-Myers Squibb), Approved January 1997
Treatment for infants and children infected with HIV

HIV (Pediatric)

Descovy (emtricitabine and tenofovir alafenamide) (by Gilead), Approved April 2016
For the treatment of HIV-1 infection

Edurant (rilpivirine) (by Tibotec), Approved May 2011
For the treatment of HIV-1

Tivicay (dolutegravir) (by ViiV HealthCare), Approved August 2013
For the treatment of HIV-1 in adults and children over 12 years of age

HIV Infections

Aptivus (tipranavir) (by Boehringer Ingelheim), Approved June, 2005
For the adjunctive treatment of HIV-1 infections

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) (by Gilead), Approved August of 2011
For the treatment of HIV-1 in treatment-naive adults

Crixivan (Indinavir sulfate) (by Merck), Approved March 1996
Treatment for HIV infection

Descovy (emtricitabine and tenofovir alafenamide) (by Gilead), Approved April 2016
For the treatment of HIV-1 infection

Edurant (rilpivirine) (by Tibotec), Approved May 2011
For the treatment of HIV-1

Egrifta (tesamorelin for injection) (by Theratechnologies), Approved November 2010
For the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy

Evotaz (atazanavir and cobicistat) (by Bristol-Myers Squibb), Approved January 2015
For the treatment of HIV-1 infection

Fortovase (by Roche), Approved November 1997
Treatment for HIV infection

Fuzeon (enfuvirtide) (by Trimeris, Roche), Approved March 2003
For the treatment of HIV-1 infection in combination with other antiretroviral agents

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) (by Gilead Sciences), Approved November 2015
For the treatment of HIV-1 infection

Intelence (etravirine) (by Tibotec), Approved January 2008
For the treatment of HIV-1

Isentress (raltegravir) (by Merck), Approved October 2007
For the treatment of HIV-1

Kaletra Capsules and Oral Solution (by Abbott Laboratories), Approved September 2000
For the treatment of HIV-1 infection

Lexiva (fosamprenavir calcium) (by GlaxoSmithKline), Approved October 2003
For the treatment of HIV infection in adults in combination with other antiretroviral agents.

Norvir (ritonavir) (by Abbott Laboratories), Approved March 1996/March 1997
Treatment for HIV infection

Prezista (darunavir) (by Tibotec), Approved June 2006
For the treatment of treatment-resistant HIV infections

Rescriptor Tablets (delavirdine mesylate tablets) (by Pharmacia & Upjohn), Approved April 1997
Treatment for HIV-1 infection

Reyataz (atazanavir sulfate) (by Bristol-Myers Squibb), Approved July 2003
For the treatment of HIV-1 infection in combination with other antiretroviral agents

Selzentry (maraviroc) (by Pfizer), Approved August 2007
For the treatment of CCR5-tropic HIV-1

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) (by Gilead), Approved August 2012
For the treatment of HIV-1 infection

Sustiva (by Bristol-Myers Squibb), Approved February 2002
Once-daily oral tablet for the the treatment of HIV infection

Trizivir (abacavir sulfate; lamivudine; zidovudine AZT) Tablet (by GlaxoSmithKline), Approved November 2000
For the treatment of HIV-1 infection

Videx (didanosine) (by Bristol-Myers Squibb), Approved June 1996
Treatment of HIV infection

VIRACEPT (nelfinavir mesylate) (by Agouron Pharmaceuticals), Approved March 1997
Treatment for HIV infection in adults and children

Viramune (nevirapine) (by Boehringer Ingelheim), Approved June 1996
Treatment for HIV infection

Viread (tenofovir disoproxil fumarate) (by Gilead), Approved October 2001
Once-daily oral tablet for the treatment of human immunodeficiency virus (HIV) infection

Zerit (stavudine) (by Bristol-Myers Squibb), Approved December 22, 1995
Treatment for HIV-infected adults who are intolerant of approved therapies

HIV/AIDS

Combivir (by GlaxoSmithKline), Approved September 1997
Treatment for AIDS and HIV Infection

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) (by Gilead), Approved August of 2011
For the treatment of HIV-1 in treatment-naive adults

Edurant (rilpivirine) (by Tibotec), Approved May 2011
For the treatment of HIV-1

Epivir (lamivudine) (by GlaxoSmithKline), Approved on November 17, 1995
Treatment used in combination with AZT for AIDS/HIV infection

Evotaz (atazanavir and cobicistat) (by Bristol-Myers Squibb), Approved January 2015
For the treatment of HIV-1 infection

Invirase (saquinavir) (by Roche), Approved on December 7, 1995
Treatment for HIV/AIDS

Myalept (metreleptin for injection) (by Bristol-Myers Squibb), Approved February of 2014
For the treatment of congenital or acquired generalized lipodystrophy

Mytesi (crofelemer) (by Napo Pharmaceuticals), Approved December 2012
For the treatment of non-infectious diarrhea in adults with HIV/AIDS

Prezcobix (darunavir and cobicistat) (by Janssen), Approved January 2015
For the treatment of HIV-1 infection

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) (by Gilead), Approved August 2012
For the treatment of HIV-1 infection

Hodgkin's Disease

Adcetris (brentuximab vedotin) (by Seattle Genetics), Approved August 2011
For the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma

Hormone Deficiencies

Aveed (testosterone undecanoate) injection (by Endo Pharmaceuticals), Approved March 2014
For the treatment of hypogonadism

Bio-T-Gel (testosterone gel) (by Teva Pharmaceutical), Approved February 2012
For the treatment of hypogonadism

Natpara (parathyroid hormone) (by NPS Pharmaceuticals), Approved January 2015
For the control hypocalcemia in patients with hypoparathyroidism

Vogelxo (testosterone) gel (by Upsher-Smith), Approved June 2014
For males with a deficiency or absence of endogenous testosterone

Hormone Replacement Therapy

Activella (Estradiol/Norethindrone Acetate) Tablets (by Novo Nordisk), Approved April 2000
Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause

Aveed (testosterone undecanoate) injection (by Endo Pharmaceuticals), Approved March 2014
For the treatment of hypogonadism

Estradiol tablets (by Duramed Pharmaceuticals), Approved December 1997
Generic equivalent of Estrace tablets

Prempro (by Wyeth), Approved January 1998
Treatment for hormone replacement therapy

Prempro & Premphase (conjugated estrogens/medroxyprogesterone acetate tablets) (by Wyeth), Approved November 1995
Treatment for postmenopausal hormone replacement, postmenopausal osteoporosis

Vogelxo (testosterone) gel (by Upsher-Smith), Approved June 2014
For males with a deficiency or absence of endogenous testosterone

Hot Flash

Brisdelle (low-dose paroxetine mesylate) (by Noven Pharmaceuticals), Approved July 2013
For the treatment of vasomotor symptoms of menopause

Duavee (conjugated estrogens/bazedoxifene) (by Pfizer), Approved October 2013
For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis

Huntington's Disease

Austedo (deutetrabenazine) (by Teva Pharmaceuticals), Initial approval April 2017
For the treatment of chorea associated with Huntington’s disease and tardive dyskinesia

Hyperparathyroidism

Parsabiv (etelcalcetide) (by Amgen), Approved February 2017
For the treatment of secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis

Hypogonadism

Androderm (Testosterone Transdermal System) (by TheraTech), Approved on September 29, 1995
Treatment for primary and secondary hypogonadism

Aveed (testosterone undecanoate) injection (by Endo Pharmaceuticals), Approved March 2014
For the treatment of hypogonadism

Bio-T-Gel (testosterone gel) (by Teva Pharmaceutical), Approved February 2012
For the treatment of hypogonadism

Fortesta (testosterone gel) (by Endo Pharmaceuticals), Approved December 2010
For the treatment of hypogonadism

Natesto, (testosterone) nasal gel (by Trimel Pharmaceuticals), Approved May 2014
For the treatment of deficiency or absence of endogenous testosterone